TEVA PHARMACEUTICAL INDUSTRIES LIMITED financials

TEVA CIK 0000818686

Source: EDGAR filings · Built 2026-06-19T01:38:33Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 1.15B 749.00M 842.00M 1.04B 236.00M 638.00M
EBITDA 3.16B 756.00M 1.59B -889.00M 3.05B -2.02B
Working Capital 490.00M -244.00M 238.00M 582.00M 1.55B -159.00M
Net Debt 13.72B 14.93B 17.11B 18.93B 21.52B 23.93B
Gross Margin 51.79% 48.74% 48.25% 46.72% 47.83% 46.38%
Operating Margin 12.50% -1.83% 2.73% -14.72% 10.81% -21.44%
Net Margin 8.17% -9.91% -3.53% -16.39% 2.63% -23.95%
Return on Equity (ROE) 17.83% -30.50% -7.45% -31.34% 4.06% -39.80%
Return on Assets (ROA) 3.46% -4.17% -1.29% -5.56% 0.87% -7.88%
Current Ratio 1.04× 0.98× 1.02× 1.05× 1.14× 0.99×
Debt-to-Equity 2.18× 3.39× 2.71× 2.78× 2.30× 2.60×
Effective Tax Rate -14.72% -52.65% 1.12% 20.33% 32.07% 3.81%
Cash Conversion Ratio 1.17× -0.76× -2.45× -0.65× 1.91× -0.30×
Accruals Ratio -0.01× -0.07× -0.04× -0.09× -0.01× -0.10×
SBC % of Revenue 0.91% 0.74% 0.76% 0.83% 0.75% 0.77%
CapEx Coverage 3.29× 2.50× 2.60× 2.90× 1.42× 2.10×
Free Cash Flow Per Share $0.99 $0.66 $0.75 $0.94 $0.21 $0.58

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 17.26B 16.54B 15.85B 14.93B 15.88B 16.66B
Revenues 1.50B
Cost of Goods and Services Sold 8.32B 8.48B 8.20B 7.95B 8.28B 8.93B
Gross Profit 8.94B 8.06B 7.64B 6.97B 7.59B 7.73B
Research and Development Expense 98.00M
Operating Income (Loss) 2.16B -303.00M 433.00M -2.20B 1.72B -3.57B
Income Tax Expense (Benefit) -180.00M 676.00M -7.00M -643.00M 211.00M -168.00M
Net Income (Loss) Attributable to Parent 1.41B -1.64B -559.00M -2.45B 417.00M -3.99B
Earnings Per Share, Basic $1.23 $-1.45 $-0.50 $-2.20 $0.38 $-3.64
Weighted Average Number of Shares Outstanding, Basic 1.15B 1.13B 1.12B 1.11B 1.10B 1.09B
Earnings Per Share, Diluted $1.21 $-1.45 $-0.50 $-2.20 $0.38 $-3.64
Weighted Average Number of Shares Outstanding, Diluted 1.16B 1.13B 1.12B 1.11B 1.11B 1.09B

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 3.56B 3.30B 3.23B 2.80B 2.17B 2.18B
Assets, Current 13.95B 12.55B 12.48B 12.05B 12.57B 13.01B
Assets 40.75B 39.33B 43.48B 44.01B 47.67B 50.64B
Liabilities, Current 13.46B 12.80B 12.25B 11.47B 11.03B 13.16B
Liabilities 32.83B 33.61B 35.35B 35.41B 36.42B 39.58B
Stockholders' Equity Attributable to Parent 7.91B 5.37B 7.51B 7.80B 10.28B 10.03B

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 1.65B 1.25B 1.37B 1.59B 798.00M 1.22B
Payments to Acquire Property, Plant, and Equipment 548.00M 562.00M 578.00M
Net Cash Provided by (Used in) Investing Activities 737.00M 792.00M 968.00M 656.00M 1.52B 863.00M
Net Cash Provided by (Used in) Financing Activities -2.15B -1.79B -1.91B -1.49B -2.17B -1.89B

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (TEVA CIK 0000818686), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

NMP

NMP Acquisition Corp.

WENN

WEN ACQUISITION CORP

ELDN

ELEDON PHARMACEUTICALS, INC.